24 completed, 14 terminated, 2 withdrawn, 1 recruiting. 29 Phase 1, 13 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 29 | Completed 22, Terminated 5, Withdrawn 2 |
| Phase 2 | 13 | Terminated 9, Completed 4 |
| Phase 3 | 2 | Terminated 2 |
Follow Alaunos Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs Neoantigen specific TCR-T cell drug product - Gynecologic Cancer, Colorectal Cancer | Completed | Alaunos Therapeutics | 8 | 2022-10-07 | 2026-10-15 | |
| Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors Neoantigen specific TCR-T cell drug product, Aldesleukin (IL-2) - Gynecologic Cancer, Colorectal Cancer | Phase 1 / Phase 2 | Terminated | Alaunos Therapeutics | 8 | 2022-04-04 | 2025-11-10 |
| HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors Ovarian Cancer, Endometrial Cancer | Terminated | Alaunos Therapeutics | 19 | 2021-10-07 | 2026-10-15 | |
| Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma Ad-RTS-hIL-12, Veledimex, Cemiplimab-Rwlc - Glioblastoma | Phase 2 | Terminated | Alaunos Therapeutics | 40 | 2019-08-01 | 2025-04-18 |
| Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102 Ad-RTS-hIL-12, veledimex - Glioblastoma | Phase 1 | Completed | Alaunos Therapeutics | 36 | 2018-09-05 | 2025-08-28 |
| A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102 Ad-RTS-hIL-12, veledimex, Nivolumab - Glioblastoma | Phase 1 | Completed | Alaunos Therapeutics | 21 | 2018-06-18 | 2025-08-12 |
| A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG Ad-RTS-hIL-12, Oral Veledimex - Arm 1 (Pediatric Brain Tumor), Oral Veledimex - Arm 2 (DIPG) - Pediatric Brain Tumor, Diffuse Intrinsic Pontine Glioma | Phase 1 / Phase 2 | Terminated | Alaunos Therapeutics | 6 | 2017-09-26 | 2025-08-12 |
| A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer Ad-RTS-hIL-12, Veledimex - Metastatic Breast Cancer | Phase 1 / Phase 2 | Terminated | Alaunos Therapeutics | 9 | 2015-07-18 | 2025-08-28 |
| A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma Ad-RTS-hIL-12, veledimex - Glioblastoma Multiforme, Anaplastic Oligoastrocytoma | Phase 1 | Completed | Alaunos Therapeutics | 40 | 2015-06-01 | 2025-04-16 |
| Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer. Ad-RTS-hIL-12 and Veledimex, Palifosfamide - Breast Cancer Nos Metastatic Recurrent | Phase 2 | Terminated | Alaunos Therapeutics | 12 | 2013-04-04 | 2025-08-28 |
| Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors palifosfamide - Adult Central Nervous System Germ Cell Tumor, Adult Teratoma | Phase 2 | Terminated | Indiana University | 5 | 2013-02-01 | 2015-07-02 |
| Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study) Carboplatin, Palifosfamide-tris, Etoposide - Extensive-Stage Small Cell Lung Cancer | Phase 3 | Terminated | Alaunos Therapeutics | 188 | 2012-06-08 | 2026-10-01 |
| Long-Term Follow-Up of Recipient of Gene Transfer Research Blood Tests, Questionnaires - Retroviridae Infections, Cancer | Recruiting | M.D. Anderson Cancer Center | 130 | 2011-12-09 | 2026-07-15 | |
| Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma INXN-2001, INXN-1001 - Melanoma | Phase 1 / Phase 2 | Completed | Alaunos Therapeutics | 26 | 2011-08-01 | 2025-10-29 |
| CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies Leukapheresis, Stem Cell Transplant, CD19-specific T Cell Infusion - Lymphoma, B-cell Lymphoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 34 | 2011-06-20 | 2023-12-19 |
| Effect on QTc, Pharmacokinetics, Safety, and Preliminary Efficacy of Single-agent Palifosfamide-tris in Subjects With Advanced Solid Tumors palifosfamide-tris, Normal Saline - Advanced Solid Tumors | Phase 1 | Completed | Alaunos Therapeutics | 24 | 2011-06-01 | 2026-09-29 |
| Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies palifosfamide-tris - Malignancy, Cancer | Phase 1 | Completed | Alaunos Therapeutics | 22 | 2010-12-01 | 2026-09-29 |
| Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma Palifosfamide-Tris, doxorubicin, Placebo - Soft Tissue Sarcoma | Phase 3 | Terminated | Alaunos Therapeutics | 447 | 2010-08-16 | 2026-10-06 |
| Study of Oral Darinaparsin in Patients With Advanced Solid Tumors darinaparsin - Advanced Solid Tumors | Phase 1 | Completed | Alaunos Therapeutics | 12 | 2010-06-01 | 2012-07-19 |
| Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat Lymphoma darinaparsin, CHOP - Lymphoma | Phase 1 | Withdrawn | Alaunos Therapeutics | 2010-06-01 | 2012-07-19 |
Showing 20 of 41. Sign in to see all of them.
Neoplasms (8) · Glioblastoma (5) · Lymphoma (5) · Carcinoma, Non-Small-Cell Lung (4) · Ovarian Neoplasms (4) · Breast Neoplasms (3) · Cholangiocarcinoma (3) · Multiple Myeloma (3) · Pancreatic Neoplasms (3) · Sarcoma (3) · Adenocarcinoma of Lung (2) · Colorectal Neoplasms (2) · Endometrial Neoplasms (2) · Hematologic Neoplasms (2) · Lymphoma, Non-Hodgkin (2)
darinaparsin (11) · isophosphamide mustard (8) · indibulin (6) · veledimex (6) · palifosfamide lysine (5) · Doxorubicin (3) · Etoposide (2) · Ifosfamide (2) · Interleukin-2 (2) · aldesleukin (2) · Blood Specimen Collection (1) · Capecitabine (1) · Carboplatin (1) · Carmustine (1) · Cytarabine (1)
United States (37) · Canada (4) · Italy (3) · Australia (2) · France (2) · Israel (2) · Poland (2) · Romania (2) · Russia (2) · United Kingdom (2) · Argentina (1) · Belgium (1) · Brazil (1) · Chile (1) · Colombia (1)
Jaymes Holland (8) · Jonathan Lewis, MD, PhD (5) · Jonathan Lewis, MD (4) · Jonathan J. Lewis, MD, PhD (3) · Partow Kebriaei, MD (2) · Scott Kopetz, MD, PhD (2) · Andrew Marsh (1) · E. Scott Kopetz, MD, PhD (1) · Jonathan J Lewis, MD, PhD (1) · Lawrence H Einhorn, MD (1) · Razelle Kurzrock, MD (1) · Sachin Shah, MD (1)
PMID 30120268, PMID 27482888, PMID 34850166, PMID 19584162, PMID 27621408, PMID 31413142, PMID 35537408
R01CA141303 (2), R01CA124782 (1)